NuVasive (NUVA) Stock Price
NuVasive Price
Revenue has compounded at 23.2% per year over the past 19 years to 1.20 B USD. Earnings per share have grown at 11.9% per year over the last 13 years. NuVasive's net margin stands at 3.4%, up from 1.1% several years earlier.
NuVasive stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of NuVasive over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how NuVasive stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing NuVasive's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | NuVasive Price |
|---|
NuVasive Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
NuVasive Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.62 | 0.69 | 0.76 | 0.81 | 0.96 | 1.03 | 1.10 | 1.17 | 1.05 | 1.14 | 1.20 | 1.28 | 1.35 | 1.48 | 1.57 | 1.72 |
| 14.81 | 10.48 | 11.24 | 6.43 | 18.62 | 6.96 | 7.00 | 6.09 | -10.10 | 8.38 | 5.54 | 6.33 | 5.87 | 9.17 | 6.23 | 9.63 |
| 75.16 | 73.58 | 76.12 | 75.96 | 74.95 | 73.86 | 71.75 | 73.20 | 69.33 | 71.70 | 72.02 | 72.02 | 72.02 | 72.02 | 72.02 | 72.02 |
| 0.47 | 0.50 | 0.58 | 0.62 | 0.72 | 0.76 | 0.79 | 0.86 | 0.73 | 0.82 | 0.87 | 0.92 | 0.97 | 1.06 | 1.13 | 1.24 |
| 46.00 | 33.00 | 58.00 | 103.00 | 98.00 | 121.00 | 45.00 | 117.00 | 34.00 | 31.00 | 64.00 | 171.00 | 198.00 | 228.00 | 272.00 | 299.00 |
| 7.42 | 4.82 | 7.61 | 12.70 | 10.19 | 11.76 | 4.09 | 10.02 | 3.24 | 2.72 | 5.33 | 13.39 | 14.64 | 15.45 | 17.35 | 17.39 |
| 3.00 | 7.00 | -16.00 | 66.00 | 37.00 | 83.00 | 12.00 | 65.00 | -37.00 | -64.00 | 40.00 | 123.00 | 141.00 | 166.00 | 189.00 | 221.00 |
| -104.35 | 133.33 | -328.57 | -512.50 | -43.94 | 124.32 | -85.54 | 441.67 | -156.92 | 72.97 | -162.50 | 207.50 | 14.63 | 17.73 | 13.86 | 16.93 |
| 43.63 | 45.80 | 50.62 | 53.09 | 55.91 | 51.86 | 52.53 | 54.64 | 51.87 | 51.74 | 62.77 | 62.77 | 62.77 | 62.77 | 62.77 | 62.77 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales NuVasive generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue NuVasive retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare NuVasive's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares NuVasive has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against NuVasive's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
NuVasive stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
NuVasive Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
NuVasive business model & stock analysis
NuVasive SWOT Analysis
Strengths
NuVasive Inc is a leading medical device company that specializes in minimally invasive and procedurally-integrated spine solutions. The company has a strong reputation for innovation and efficient surgical techniques, which gives them a competitive advantage in the market.
NuVasive Inc's proprietary surgical products and technologies offer several benefits, including reduced patient recovery time, lower healthcare costs, and improved patient outcomes. These advantages contribute to the company's continued growth and success.
Weaknesses
NuVasive Inc heavily relies on its key products and technologies, which may expose them to potential risks in case of any product-related issues or technological disruptions. Any negative impact on their core offerings could affect the company's financial performance and market position.
Moreover, NuVasive Inc's heavy reliance on a specific market segment, such as spine surgeries, can make them vulnerable to any significant changes in healthcare policies, regulations, or preferences that could reduce the demand for their products.
Opportunities
The global spine surgery market is expected to experience steady growth due to an aging population, increasing prevalence of spinal disorders, and advancements in medical technology. NuVasive Inc can leverage these opportunities to expand its product portfolio and capture a larger market share.
Furthermore, NuVasive Inc has the potential to explore new geographical markets and expand its operations internationally. By entering emerging markets and forming strategic partnerships, the company can tap into new customer segments and enhance its competitive position.
Threats
Intense competition in the medical device industry poses a significant threat to NuVasive Inc. Competitors with similar or alternative products and technologies may challenge their market share and pricing strategies.
Additionally, uncertainties surrounding regulatory approvals and compliance requirements can pose risks to NuVasive Inc's product development timelines and market penetration strategies. Adapting to evolving regulations and maintaining compliance can be a complex and costly process.
NuVasive Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
NuVasive Segments
NuVasive Revenue by Segment (1/3)
3 Years
5 Years
Max
Details
NuVasive Revenue by Segment (2/3)
3 Years
5 Years
Max
Details
NuVasive Revenue by Segment (3/3)
3 Years
5 Years
10 Years
Max
Details
NuVasive Revenue by Region
3 Years
5 Years
10 Years
Max
Details
NuVasive Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
NuVasive historical P/E ratio, EBIT multiple, and P/S ratio
NuVasive annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
NuVasive shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
NuVasive Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/4/2023 | Maintained | Equal Weight | 60 | |
| 8/4/2023 | Maintained | Overweight | 33 | |
| 8/3/2023 | Maintained | Equal Weight | 60 | |
| 8/3/2023 | Maintained | Overweight | 33 | |
| 7/19/2023 | Maintained | Hold | – | |
| 7/18/2023 | Maintained | Hold | – | |
| 5/31/2023 | Maintained | Equal Weight | 60 | |
| 5/30/2023 | Maintained | Equal Weight | 60 | |
| 5/15/2023 | Maintained | Outperform | 52 | |
| 5/14/2023 | Maintained | Outperform | 52 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
NuVasive Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 5/8/2024 | 0.51USD | - | 332.77 MUSD | - | 2024 Q1 |
| 2/20/2024 | 0.62USD | - | 342.85 MUSD | - | 2023 Q4 |
| 11/7/2023 | 0.58USD | - | 319.02 MUSD | - | 2023 Q3 |
| 8/1/2023 | 0.61USD | - | 330.51 MUSD | - | 2023 Q2 |
| 5/2/2023 | 0.51USD | - | 308.82 MUSD | - | 2023 Q1 |
| 2/21/2023 | 0.55USD | - | 317.81 MUSD | - | 2022 Q4 |
| 11/9/2022 | 0.55USD | - | 303.23 MUSD | - | 2022 Q3 |
| 8/3/2022 | 0.57USD | - | 311.02 MUSD | - | 2022 Q2 |
| 5/4/2022 | 0.39USD | - | 282.14 MUSD | - | 2022 Q1 |
| 2/23/2022 | 0.49USD | - | 303.43 MUSD | - | 2021 Q4 |
EESG©
Eulerpool ESG Scorecard© for the NuVasive stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
NuVasive shareholder structure
| % | Name |
|---|---|
14.58797% | |
10.85387% | |
5.61292% | |
4.03375% | |
3.69385% | |
2.52398% |
NuVasive Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
14.40% | SEC ↗ | |
12.25% | SEC ↗ | |
12.04% | SEC ↗ | |
11.80% | SEC ↗ | |
11.80% | SEC ↗ | |
11.80% | SEC ↗ | |
11.60% | SEC ↗ | |
11.00% | SEC ↗ | |
10.21% | SEC ↗ | |
6.67% | SEC ↗ |
NuVasive Executives and Management Board
14 members · avg. age 53 · 29 % women
Mr. J. Christopher Barry (50)
Chief Executive Officer, Director · since 2018
8.08 M USD
Management
Mr. Matthew Harbaugh (52)
Executive Vice President, Chief Financial Officer
Mr. Nathaniel Sisitsky (49)
Senior Vice President, General Counsel, Corporate Secretary
Mr. Dale Wolf (43)
Senior Vice President - Global Operations
Mr. Michael Farrington (39)
Senior Vice President, People and Culture
Ms. Juliet Cunningham
Vice President, Investor Relations · since 2021
Board of Directors
Mr. Daniel Wolterman
Independent Chairman of the Board
Ms. Vickie Capps (61)
Independent Director
Ms. Leslie Norwalk (57)
Independent Director
Dr. John DeFord (61)
Independent Director
Mr. Robert Friel (67)
Independent Director
Mr. R. Scott Huennekens (58)
Independent Director
NuVasive Supply Chain
NuVasive Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.24 | 0.37 | 0.43 | ||
| 2 | -0.09 | 0.76 | 0.31 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.25 | -0.15 | 0.05 |
Frequently asked questions about NuVasive
NuVasive Inc is a leading medical device company specializing in spine technology solutions. Their business model revolves around designing, developing, and providing innovative surgical products and procedures to treat various spine disorders, improving patient outcomes. With a focus on minimally invasive solutions, NuVasive offers a comprehensive portfolio of implants, software systems, and surgical instruments. By combining advanced technology, clinical expertise, and their proprietary data insights platform, they aim to deliver efficient, personalized solutions to healthcare providers, enabling them to offer better patient care. NuVasive's strong commitment to research, development, and partnerships reinforces their position as a trusted leader in the spine industry.
NuVasive Inc is primarily active in the healthcare and medical device industries.
The main competitors of NuVasive Inc in the market include Medtronic, Johnson & Johnson, Stryker Corporation, and Zimmer Biomet Holdings Inc.
NuVasive Inc is a global medical device company specializing in developing minimally invasive surgical products and procedures for the spine. Founded in 1997 by Alex Lukianov, the company has since become a leader in the spine market. NuVasive is known for its innovative technologies and solutions that aim to improve patient outcomes and reduce the invasiveness of spine surgeries. With a focus on disruptive innovation, NuVasive has gained recognition and has a strong presence in the healthcare industry. Over the years, NuVasive Inc has expanded its product portfolio and continues to push boundaries in the field of spine surgery.
NuVasive Inc has achieved several significant milestones since its establishment. Notably, the company introduced the first-ever Maximum Access Surgery (MAS) platform, enabling minimally disruptive spinal fusion procedures. Additionally, NuVasive Inc developed the XLIF (eXtreme Lateral Interbody Fusion) technique, which revolutionized spine surgery by providing surgeons with access to the spine through a small incision on the patient's side. The company has also received multiple accolades, including being listed among Fortune's 100 Fastest-Growing Companies. NuVasive Inc continues to innovate and develop advanced spinal surgery technologies, solidifying its position as a leading player in the medical device industry.
NuVasive Inc is primarily present in the United States, as it is headquartered in San Diego, California. However, the company has a significant global presence with operations and distribution channels in various regions and countries. NuVasive Inc operates in Europe, including countries like Germany, United Kingdom, France, and Italy. It also has a presence in Asia, particularly in Japan, Australia, and China. Additionally, NuVasive Inc serves customers in Latin America, including Brazil and Mexico. With its widespread reach, NuVasive Inc caters to a diverse range of healthcare markets across multiple continents.
NuVasive Inc represents values of innovation, patient focus, and collaboration. With a corporate philosophy centered around transforming spinal surgery through disruptive technology, NuVasive aims to improve patient outcomes and enhance surgical procedures. The company embraces the concept of "The Better Way" by developing advanced medical solutions and fostering a culture of continuous improvement. NuVasive prioritizes patient-centric care by combining innovative technology with minimally invasive techniques. By constantly pushing boundaries and working closely with surgeons, NuVasive Inc strives to revolutionize the field of spinal surgery and enhance the quality of life for those in need.
22 analysts currently rate the NuVasive stock: 9 recommend buying, 13 holding and 0 selling.
Converted at the current exchange rate, the NuVasive share trades at 34.31 EUR (39.75 USD).
The NuVasive share (NUVA) is listed on 5 stock exchanges, including: NASDAQ (NUVA), Frankfurt (NK8.F), München (NK8.MU), Düsseldorf (NK8.DU), SIX (Zürich) (NK8.SW).
NuVasive Inc is a company specializing in the development and manufacturing of technologies and instruments for spinal surgery. The company offers a wide range of products and services aimed at improving surgical procedures and outcomes for patients. NuVasive's business model is based on developing new, innovative technologies and providing training and support to medical professionals. NuVasive operates in several business areas, each targeting a specific segment of spinal surgery. These include spinal fusion, navigation, implants, and biologics. Within these business areas, the company offers a variety of products including wedges, cages, plates, screws, drills, and navigation instruments. Some of NuVasive's notable products include the Mas platform, Prelude system, and XLIF implant system. To sell its products and services in the market, NuVasive works closely with medical professionals to ensure they are aware of the latest procedures and innovations. The company also invests in training programs and conferences to keep professionals up to date and able to achieve the best outcomes for their patients. Additionally, the company offers comprehensive customer support, available 24/7. NuVasive aims to be a leader in spinal surgery by developing innovative technologies that improve traditional surgical procedures. To achieve this, the company continually invests in research and development to identify new solutions and products that meet the needs of both patients and medical professionals. Overall, NuVasive's business model is based on the development and marketing of advanced technologies and instruments that contribute to making spinal surgery safer, more effective, and more precise. Through its strong partnerships with medical professionals and comprehensive support and training programs, NuVasive works to improve procedures and outcomes in spinal surgery and enhance the lives of patients.
The revenue cannot currently be calculated for NuVasive.
The profit cannot currently be calculated for NuVasive.
The P/E ratio cannot be calculated for NuVasive at the moment.
The P/S cannot be calculated for NuVasive currently.
The Eulerpool Quality Score for NuVasive is 1/10.
The ISIN of NuVasive is US6707041058. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of NuVasive is A0CAYR. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of NuVasive is NUVA. The ticker symbol is used to trade NuVasive shares on the stock exchange.
NuVasive paid dividends every year for the past 0 years.
NuVasive is assigned to the 'Health' sector.
The dividends of NuVasive are distributed in USD.
NuVasive stock
NuVasive Peer Group
NuVasive Ticker
NuVasive FIGI
All fundamentals and in-depth analysis of NuVasive
Our stock analysis for NuVasive stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NuVasive. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.